FDA Clears Hoffmann-La Roche Respiratory Diagnostic Panel
What happened
The U.S. Food and Drug Administration granted 510(k) clearance for the cobas® eplex respiratory pathogen panel 3, a diagnostic test developed by Hoffmann-La Roche. The panel detects up to 19 viruses and bacteria, including improved inclusivity for influenza A and SARS-CoV-2 strains, and offers up to five customizable panel configurations.
From prnewswire.com
Why it matters
The clearance allows healthcare laboratories to rapidly identify respiratory infections, which could help health systems reduce unnecessary antibiotic use and decrease the length of patient stays during peak respiratory seasons. The test is designed to enhance operational efficiency by delivering results in under two hours.
From prnewswire.com
Who's involved
- FDARegulatory agency that granted 510(k) clearance for the diagnostic test
- Hoffmann-La RocheSwiss healthcare company that developed and received clearance for the diagnostic panel
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Hoffmann-La RocheSpeculative
Hoffmann-La Roche could see increased revenue from the market access granted by the FDA clearance.
Keep exploring
The entities involved
- FDA
-
Hoffmann-La Roche
Swiss healthcare company
Related events
- FDA granted 510(k) clearance for combined technologies for Solventum.
- Major pharmaceutical companies face safety questions and intense competition in the obesity drug market.
- Providence Medical Technology, Inc. received 510(k) clearance from the FDA and plans to showcase its system at the Henry B. González Convention Center.
- Roche Pharma Vietnam partners with the Bright Future Fund, which is led by Nguyen Thi Xuyen.
- A company is seeking FDA 510(k) clearance while simultaneously conducting a private placement and qualifying its prospectus in British Columbia.